Tridente giuseppe (34 Ergebnisse)

Brossura. Zustand: new. Roma, 1979; br., pp. 394, ill. Libro.

Zustand: NEW.

Zustand: New.

hardcover. Zustand: New. Special order direct from the distributor.

Zustand: As New. Unread book in perfect condition.

Paperback. Zustand: Brand New. 715 pages. 10.50x8.25x2.00 inches. In Stock.

Zustand: New.

Hardcover. Zustand: new. Hardcover. Adverse Events and Oncotargeted Kinase Inhibitors Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Zustand: As New. Unread book in perfect condition.

Zustand: New.

Zustand: New.

Zustand: New. In.

Zustand: New. In.

Rilegato. Zustand: new. Milano, 2013; ril., cm 16x24. Libro.

Zustand: New. Num Pages: 672 pages. BIC Classification: MMG. Category: (P) Professional & Vocational. Dimension: 276 x 216. . . 2017. 1st Edition. hardcover. . . . .

Taschenbuch. Zustand: Neu. Adverse Events with Biomedicines | Prevention Through Understanding | Giuseppe Tridente | Taschenbuch | xxx | Englisch | 2017 | Springer | EAN 9788847058484 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those 'biomedicines' - monoclonal antibodies, fusion proteins, and cytokines - that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered.Electronic data sheets, downloadable from Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies.…

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those 'biomedicines' - monoclonal antibodies, fusion proteins, and cytokines - that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered.Electronic data sheets, downloadable from Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies. …

Paperback. Zustand: Brand New. 715 pages. 10.50x8.25x2.00 inches. In Stock.

Zustand: New. Num Pages: 672 pages. BIC Classification: MMG. Category: (P) Professional & Vocational. Dimension: 276 x 216. . . 2017. 1st Edition. hardcover. . . . . Books ship from the US and Ireland.

Hardcover. Zustand: Brand New. 2014 edition. 633 pages. 9.25x6.25x1.50 inches. In Stock.

Paperback. Zustand: Brand New. reprint edition. 664 pages. 9.00x6.00x1.25 inches. In Stock.

Hardcover. Zustand: new. Hardcover. Adverse Events and Oncotargeted Kinase Inhibitors Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

Paperback. Zustand: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Zustand: New. pp. 633.

Zustand: new. Questo è un articolo print on demand.

Zustand: new. Questo è un articolo print on demand.

Zustand: new. Questo è un articolo print on demand.

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those 'biomedicines' - monoclonal antibodies, fusion proteins, and cytokines - that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered.Electronic data sheets, downloadable from Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies. 664 pp. Englisch.…

Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those 'biomedicines' - monoclonal antibodies, fusion proteins, and cytokines - that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered.Electronic data sheets, downloadable from Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies. 664 pp. Englisch.…